Introduction: Peptide receptor radionuclide therapy targets somatostatin receptors expressed on well-differentiated neuroendocrine neoplasms. Retrospective monocentric studies indicate that peptide receptor radionuclide therapy is an effective treatment for patients with neuroendocrine neoplasms.
Aim(s): We initiated a multi-institutional, prospective and board reviewed registry for patients treated with peptide receptor radionuclide therapy.
Materials and methods: Four hundred and fifty patients were included and followed for 17.7 months in median. Most patients were treated with Lutetium-177 (54%) or by both radionuclides. Origin of neuroendocrine neoplasms was pancreas (38%), small bowel 30%), unknown primary (19%) and lung (4%). Most neuroendocrine neoplasms were well-differentiated with a proliferation rate below 20% in 54% and were pretreated by one or more therapies in 73%.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Prof. Dr. Dieter Hörsch
To read results and conclusion, please login ...
Further abstracts you may be interested in